In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene To Pursue Revlimid Combination Use For Melanoma After Halting Monotherapy Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

Ongoing Phase III in multiple myeloma will not be derailed by the discontinuation of melanoma trials for lack of efficacy, company says. Planned earlier-phase malignant melanoma trials will test Revlimid in combination with dacarbazine, temozolomide.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS059257

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel